Business Wire

CIPPE

Share
CING2017 and CIPE2017 to Kick Off Concurrently With cippe2017, Aiming to Boost Cooperation on Gas Technology and Equipment

The 7th China International Natural Gas Technology and Equipment Exhibition (CING2017) and the 17th China International Exhibition on Equipment of Pipeline, and Oil & Gas Storage and Transportation (CIPE2017, Asia’s largest natural gas pipeline exhibition), will be held concurrently with the 17th China International Petroleum & Petrochemical Technology and Equipment Exhibition (cippe2017) at the New China International Exhibition Center in Beijing on March 20-22, 2017. With an exhibition area of 100,000m2 and featuring 18 international pavilions, the events are expected to gather 2,000 exhibitors, including 46 Fortune 500 companies, from 65 countries and regions, and attract 80,000 visitors.

Exhibitors of previous events include major Chinese companies like CNPC, Sinopec, CNOOC, Jereh and foreign companies like, Gazprom, ExxonMobil, Schlumberger, and Cater Pillar. While major international players like Total, Shell, BP, and Qatar Petroleum are frequent visitors to the event.

In recent years, the determination of governments worldwide to cut down PM2.5 index has already pressed many industries to abandon coal as a major energy source. In addition, the validation of the Paris Agreement on November 4 this year will surely accelerate the global shift to clean energy, of which gas will account for a dominant proportion.

Zhao Yujian, Head of China Petroleum Pipeline Bureau, commented, “The construction of storage and transmission facilities in oil & gas-rich regions such as Middle East, Central Asia and Russia is under stable growth. Meanwhile, China is advancing its ‘One Belt and One Road’ Initiative as well as multiple other projects such as the Asian Infrastructure Investment Bank, the Silk Road Fund, and the China-Africa Development Fund, which will all bring historical opportunities for international pipeline development. With China speeding up its pace for a moderately prosperous society, the demand for oil and gas, especially natural gas and LNG, will remain strong, generating enormous development potential for oil & gas pipeline and storage equipment.”

China’s gas consumption will reach 360-400 billion cubic meters by 2020 and increase to 500 billion cubic meters by 2030. Experts estimate that by the end of the 13th Five-Year Plan (2016-2020), China’s long-distance oil & gas transmission pipelines mileage will surpass 160,000km.

Currently, many cross-border pipeline projects are under construction. The 4,000km China-Russia East Route natural gas pipeline, starting from Eastern Siberia and running through China’s 9 provinces, is planned to complete in 2018. The China-Kyrghyzstan gas pipeline, planned to reach 215km, is being constructed as part of the China-Central Asia gas pipeline network.

CING and CIPE will ally with the world’s largest oil exhibition cippe to provide a comprehensive platform for exhibitors and professional buyers from enterprises, government, research institutes and industry associations for business cooperation and gas technology exchange.

For more information, please visit:

CING: http://www.cingexpo.com.cn/2017/en/

CIPE: http://www.cipe.com.cn/2017/en/

Contact:

Organizing Committee of cippe 2017
General Inquiry
Maci, +86-10-58236588/6555
cippe@zhenweiexpo.com
or
Media Enquiry
Linda Liang, +86-10-58236579/18701599799
liangyan@zhenweiexp.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM31.8.2025 11:15:00 CEST | Press release

− Sustained Benefit of Vutrisiran Across Mortality, Cardiovascular Events, Quality of Life and Cardiac Biomarkers Observed Through Up to 48 Months, Including 12 Months from the Ongoing Open-Label Extension, Reinforce Potential as First-Line Treatment for ATTR-CM –− Vutrisiran, which Delivers Rapid Knockdown of Transthyretin, Reduced the Risk of Composite of All-Cause Mortality or First Cardiovascular Event by 37% in the Overall Population and 42% in the Monotherapy Group During the Same Period – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Card

WETEX Opens Broad Investment Horizons for International Companies31.8.2025 08:30:00 CEST | Press release

DEWA will organise the exhibition from 30 September to 2 October 2025 Under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) will organise the 27th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 30 September to 2 October 2025 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250830023664/en/ WETEX opens broad investment horizons for international companies (Photo: AETOSWire) WETEX embodies the UAE's pioneering position in clean and renewable energy and sustainability. It also supports Dubai's ambitious vision of a sustainable economy. The exhibition covers multiple areas including water, energy, smart cities, green mobility, artificial i

Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 18:00:00 CEST | Press release

Initiation of the development of new oral triple combination tablets, aimed at improving adherence and outcomes in low-density lipoprotein cholesterol (LDL-C) management. Recent findings from MILOS and SANTORINI registries presented at ESC Congress 2025, highlight ongoing challenges in accurately assessing cardiovascular (CV) risk and helping patients reach LDL-C targets.1-5 Furthermore, data from a four-country cohort of the MILOS study support the real-world effectiveness and safety of bempedoic acid in both sexes.6 Simulation using SANTORINI data reveals the potential of improved LDL-C goal attainment with tailored oral combination therapy of statins, ezetimibe and bempedoic acid, in line with the latest 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias.7,8 Daiichi Sankyo has a long-standing commitment to easing treatment of cardiovascular disease (CVD) and exploring new treatment options that improve CVD outcomes and treatment adherence. Daiich

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 16:30:00 CEST | Press release

- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented as a Late-Breaking Abstract at the European Society of Cardiology Congress 2025 -- Zilebesiran Demonstrated Clinically Meaningful Reductions in Office Systolic Blood Pressure in Patients with Uncontrolled Hypertension and High Cardiovascular Risk at Month 3 Primary Endpoint, with Continuous Control Through Month 6 -- Zilebesiran Displayed Encouraging Safety When Combined with Two or More Antihypertensives -- Results Support Biannual Dosing Regimen and Inform Phase 3 Trial Design: Trial Expected to Initiate by Year-End 2025 -- Alnylam to Host Webcast Investor Event on August 30, 2025, at 1:00 pm ET (7:00 pm CEST) - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from t

Andersen Consulting styrker sine kompetencer inden for virksomhedstransformation med Fabric29.8.2025 17:01:00 CEST | Pressemeddelelse

Andersen Consulting udvider sin platform gennem en samarbejdsaftale med Fabric, der er et strategisk designfirma, der arbejder med organisationer for at integrere bæredygtighed, forsyningskæder og menneske-centreret innovation på tværs af kultur og drift. Fabric blev grundlagt i Japan i 2021 og arbejder sammen med virksomheder og globale brands om at skabe regenerative forretningsmodeller sammen samt bæredygtige brandstrategier og fremtidssikrede produkter. Ved hjælp af strategiske designmetoder og designfilosofi skaber virksomheden indsigtsbaseret transformation på tværs af forsyningskæder, brand og HR. Fabric er kendt for sin systemtænkning og sit engagement i social og miljømæssig bæredygtighed og fremmer desuden digitale transformationsinitiativer, der integrerer bæredygtighed, humankapital og AI. "Fabric er skabt for at hjælpe virksomheder med at blomstre gennem regenerative relationer til mennesker, samfund og forbundne, levende systemer," sagde James Hollow, der er grundlægger a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye